125 related articles for article (PubMed ID: 7107086)
1. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
Rameis H; Hitzenberger G; Horwatitsch H
Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
[TBL] [Abstract][Full Text] [Related]
2. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
3. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
Knauf H; Möhrke W; Mutschler E; Völger KD
Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
[TBL] [Abstract][Full Text] [Related]
4. [Biological availability of spironolactone in two different galenic forms (author's transl)].
Rameis H; Hitzenberger G; Horwatitsch H
Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
[TBL] [Abstract][Full Text] [Related]
5. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo availability of spironolactone from oral dosage forms.
Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.
Karim A
Drug Metab Rev; 1978; 8(1):151-88. PubMed ID: 363379
[No Abstract] [Full Text] [Related]
10. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
Rameis H; Bacher S
Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
[TBL] [Abstract][Full Text] [Related]
11. [Relative bioavailability of a new spironolactone preparation (author's transl)].
Erking W; Lücker PW; Stöcker KP; Wetzelsberger K
Arzneimittelforschung; 1979; 29(8):1184-9. PubMed ID: 583021
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
Möhrke W; Knauf H; Mutschler E
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
[TBL] [Abstract][Full Text] [Related]
13. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
[TBL] [Abstract][Full Text] [Related]
14. [Bioavailability studies of two spironolactone-preparations (author's transl)].
Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone. II. Bioavailability.
Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
Rosenthal J; Jaeger H; Specker M
Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
[TBL] [Abstract][Full Text] [Related]
17. [Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
Lucchelli PD; Monarca A; Del Mastro S; Sega R
Boll Chim Farm; 1978 Aug; 117(8):487-95. PubMed ID: 743391
[No Abstract] [Full Text] [Related]
18. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
[TBL] [Abstract][Full Text] [Related]
19. Improved bioavailability from a spironolactone beta-cyclodextrin complex.
Yusuff NT; York P; Chrystyn H; Bramley PN; Swallow RD; Tuladhar BR; Losowsky MS
Eur J Clin Pharmacol; 1991; 40(5):507-11. PubMed ID: 1884726
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
Tidd MJ; Collins WT; Chamberlain J
J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
